Under the terms of the collaboration, 21st.BIO has developed a new protein production strain for AIMSilk that is created from highly specialized precision fermented microorganisms. The new strain ensures extracellular expression of silk proteins, enabling manufacturing at unprecedented productivity levels due to higher yield and greater efficiency, thereby reducing production costs.
“By partnering with 21st.BIO, we are succeeding where so many have struggled, delivering high performance precision fermentation at the right quality and cost parameters, and at a true industrial scale,” Ulrich Scherbel, CEO, AMSilk said in a press statement.